Literature DB >> 10202116

Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection.

P Pinge-Filho1, C E Tadokoro, I A Abrahamsohn.   

Abstract

Suppression of host lymphoproliferative responses to mitogens and Ag is characteristically seen during acute infection with the protozoan parasite Trypanosoma cruzi. We investigated the reciprocal regulation of prostaglandins (PG), TNF-alpha, and nitric oxide (NO) production and their effects on cytokine production and lymphoproliferative responses to parasite Ag and to Con A by spleen cells (SC) from T.-cruzi-infected mice. Large amounts of PGE2, TNF-alpha, and NO were produced during infection. TNF-alpha stimulated PG and NO synthesis, while both mediators inhibited TNF-alpha synthesis. Blocking PG also reduced NO synthesis indicating that PG stimulate NO production. Treatment with indomethacin or NMLA stimulated lymphoproliferation on days 6 and 22 of infection; on day 14, when suppression of proliferation and NO production was maximal, combined inhibition of NO and PG production restored parasite Ag specific and Con A proliferative responses. Blocking PG or NO production increased IL-2, IFN-gamma, and TNF-alpha, but not IL-12 production by SC; IL-10 levels were not reduced. Indomethacin-treated infected mice had higher mortality compared to untreated infected animals. The data indicate that PG, together with NO and TNF-alpha, participate in a complex circuit that controls lymphoproliferative and cytokine responses in T. cruzi infection. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202116     DOI: 10.1006/cimm.1999.1463

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  21 in total

Review 1.  Bioactive lipids in Trypanosoma cruzi infection.

Authors:  Fabiana S Machado; Shankar Mukherjee; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

2.  Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase.

Authors:  Rito Santo Pereira; Aparecida Donizette Malvezi; Maria Isabel Lovo-Martins; Bruno Fernando Cruz Lucchetti; Jussevania Pereira Santos; Eliandro Reis Tavares; Waldiceu Aparecido Verri; Eduardo José de Almeida Araújo; Lucy Megumi Yamauchi; Sueli Fumie Yamada-Ogatta; Marli Cardoso Martins-Pinge; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Immunity and immune modulation in Trypanosoma cruzi infection.

Authors:  Fabíola Cardillo; Rosa Teixeira de Pinho; Paulo Renato Zuquim Antas; José Mengel
Journal:  Pathog Dis       Date:  2015-10-04       Impact factor: 3.166

4.  Interleukin-12 stimulation of lymphoproliferative responses in Trypanosoma cruzi infection.

Authors:  A P Galvão da Silva; I de Almeida Abrahamsohn
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

5.  Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2.

Authors:  L M Plitnick; R A Jordan; J A Banas; D M Jelley-Gibbs; M C Walsh; M T Preissler; E J Gosselin
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.

Authors:  Jian-Jun Wen; M Paola Zago; Sonia Nuñez; Shivali Gupta; Federico Nuñez Burgos; Nisha Jain Garg
Journal:  Mol Cell Proteomics       Date:  2012-04-27       Impact factor: 5.911

7.  Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.

Authors:  Aparecida D Malvezi; Carolina Panis; Rosiane V da Silva; Rafael Carvalho de Freitas; Maria I Lovo-Martins; Vera L H Tatakihara; Nágela G Zanluqui; Edecio Cunha Neto; Samuel Goldenberg; Juliano Bordignon; Sueli F Yamada-Ogatta; Marli C Martins-Pinge; Rubens Cecchini; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

8.  Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.

Authors:  Virginia M B Lorena; Alinne F A Verçosa; Raquel C A Machado; Lucas Moitinho-Silva; Maria G A Cavalcanti; Edimilson D Silva; Antonio G P Ferreira; Rodrigo Correa-Oliveira; Valéria R A Pereira; Yara M Gomes
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

Review 9.  Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes.

Authors:  Mairi C Noverr; John R Erb-Downward; Gary B Huffnagle
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response.

Authors:  Ana Paula Galvão Da Silva; Jacqueline F Jacysyn; Ises De Almeida Abrahamsohn
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.